BIIB Q2 2020 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q2 2020 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$3.7B+1.8% YoY

Gross Profit

$3.3B88.8% margin

Operating Income

$2.0B53.6% margin

Net Income

$1.5B41.9% margin

EPS (Diluted)

$9.59

QoQ Revenue Growth

+4.2%

Cash Flow

Operating Cash Flow

$1.9B

Free Cash Flow

$1.8B

Stock-Based Comp.

$44M

Balance Sheet

Total Assets

$25.5B

Total Liabilities

$14.2B

Stockholders' Equity

$11.3B

Cash & Equivalents

$2.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.7B	$3.6B	+1.8%
Gross Profit	$3.3B	$3.1B	+4.1%
Operating Income	$2.0B	$2.0B	+1.0%
Net Income	$1.5B	$1.5B	+3.2%

Revenue Segments

MS Product Revenues

$2.1B45%

Fumarate

$1.2B25%

SPINRAZA

$495M10%

Interferon

$481M10%

TYSABRI product

$432M9%

Geographic Segments

UNITED STATES

$1.7B62%

Non-US

$1.1B38%